Methotrexate vs cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: A single-center analysis in Japan

Bone Marrow Transplantation

Volumn 32, Issue 2, 2003, Pages 171-176

  Koga, Y ^a   Nagatoshi, Y ^a   Kawano, Y ^a,b   Okamura, J ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Cyclosporin; GVHD prophylaxis; Japanese; Methotrexate; Pediatric patients

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; POLYMYXIN B; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VANCOMYCIN;

ACUTE DISEASE; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER CENTER; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHRONIC DISEASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG PREFERENCE; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HLA MATCHING; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; SIBLING; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HUMANS; INFANT; JAPAN; MALE; METHOTREXATE; SIBLINGS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0041368373     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704051     Document Type: Article

References (19)

1. Goker H. Haznedaroglue IC, Chao NJ. Acute graft-versus-host disease: Pathophysiology and management. Exp Hematol 2001; 29: 259-277.
2. Nash RA, Antin JH, Karanes C et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
3. Hiraoka A, Ohashi Y, Okamoto S et al. Phase II study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 181-185.
4. Ringden O, Horowitz MM, Sondel P et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia. Blood 1993; 81: 1094-1101.
5. Locatelli F, Zecca M, Rondelli R et al. Graft versus host disease prophylaxis with low-dose cyclosporin - A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000; 95: 1572-1579.
6. Storb R, Epstein RB, Graham TC et al. Methotrexate regimens for control of graft-versus host disease in dogs with allogeneic marrow grafts. Transplantation 1970; 9: 240-246.
7. Deeg HJ, Storb R, Thomas ED et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985; 65: 1325-1334.
8. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304
9. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host disease syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
10. Thomas E, Storb R, Clift RA et al. Bone marrow transplantation. N Engl J Med 1975; 292: 832-843.
11. Deeg HJ, Storb R. Graft-versus-host disease: pathophysiological and clinical aspects. Ann Rev Med 1984; 35: 11-24.
12. Maruya E, Saji H, Seki S et al. Evidence that CD31, CD49b, and Cd62L are immunodominant minor histocompatibility antigens in HLA-identical sibling bone marrow transplants. Blood 1998; 92: 2169-2176.
13. Storb R, Deeg HJ, Fisher L et al. Cyclosporin vs methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 1988; 71: 293-298.
14. Teshima T, Ferrara JL. Understanding the allo response: New approaches to graft-versus-host disease prevention. Semin Hematol 2002; 39: 12-22.
15. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
16. Ratanatharathorn V, Nash RA, Pzepiorka D et al. Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314.
17. Yanik G, Levine JE, Ratanatharathorn V et al. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 26: 161-167.
18. Storb HJ, Deeg ED, Thomas et al. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 1985; 66: 698-702.
19. Peter C, Minkov M, Gadner H et al. Statement of current majority practice in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant 2000; 26: 405-411.